Multiple sclerosis was tested in phase 2 trials with two BTK inhibitors (evobrutinib and tolebrutinib), both of which demonstrated positive disease impact on this neurodegenerative disorder and are covalent modifiers of BTK. This evidence concerns the gene BTK and multiple sclerosis.